Fresenius stock holds firm after 2026 guidance and trading data
Published on 08/30/2026 at 16:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius SE & Co. KGaA (DE0005785604) stock traded at 45.79 EUR on August 29, 2026, with a 52-week range of 35.11 EUR to 52.96 EUR and volume of 26.79K shares on the same session. The latest visible analyst snapshot points to a 55.586 EUR average target and 13 buy ratings, while the next results date is listed for November 3, 2026.
Trading range stays close
The price sat 1.93% below the start of the year in the latest chart view, and the daily move was -0.52% on August 29, 2026. That puts the stock closer to the middle of its 52-week band than to the top, even after a year that has already seen large swings from 35.11 EUR to 52.96 EUR.
For investors, that range matters because it frames the next catalyst: the November 3, 2026 earnings date arrives with the share price still below the 12-month average target implied by the latest analyst snapshot.
Guidance and earnings view
The current market page shows trailing earnings per share of 2.775 EUR and EBITDA of 3.04 billion EUR, alongside a dividend of 1.05 EUR per share and a market cap of 26.1 billion EUR. The same source also lists a price-to-earnings ratio of 16.57 and an EV/EBITDA multiple of 11.3, which helps explain why the stock still trades as a valuation story as much as a growth story.
The analyst table on the same page shows 13 buy ratings, 1 hold rating, and 0 sell ratings, with a 12-month average target of 55.586 EUR. That is 20.32% above the quoted 46.200 EUR level shown on the page, a concrete gap that will matter if the company delivers on its next update.
Business lines still define Fresenius
Fresenius SE & Co. KGaA remains a diversified healthcare group with dialysis, hospital, and medical products exposure through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. That mix makes the stock sensitive to reimbursement, hospital utilization, and product volume trends rather than to a single line of business.
The most recent market snapshot also shows a book value per share of 34.97 EUR and a one-year change of -0.8584%, which adds context to the current trading pattern. In practical terms, the stock is moving inside a range that leaves room for either a rerating or another stretch of sideways trade.
Price and setup
Fresenius stock was quoted at 46.200 EUR in the latest page view, with a daily range of 45.665 EUR to 46.495 EUR and a market cap of 26.1 billion EUR as of August 29, 2026.
Company data
Company: Fresenius SE & Co. KGaA
ISIN: DE0005785604
Ticker: FRE
Exchange: Xetra
Sector / Industry: Health Care / Health Care Providers & Services
Index membership: DAX
More on Fresenius
The group's product mix spans dialysis care, infusion and nutrition products, hospital operations, and related medical services, which keeps its earnings profile tied to both inpatient demand and treatment volumes. That broad setup is one reason the stock often reacts to guidance and margin commentary as much as to revenue growth.
Stock view
As of August 29, 2026, Fresenius traded at 46.200 EUR on the latest visible market page, with a 52-week range of 35.11 EUR to 52.96 EUR and a market cap of 26.1 billion EUR.
